IP Library Granted Patent US 8,529,557
Granted Patent B2
US 8,529,557 · App. 12/130,937 · Granted Sep 10, 2013

System and method for stray light compensation of corneal cuts

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,529,557
App. No.
12/130,937
Granted
Sep 10, 2013
Kind
B2
Abstract

A system and method to compensate for the deformation of an eye requires calculation of an induced deformation angle Ψ, wherein the deformation is intentionally induced during laser surgery by a contact lens, and a refraction angle φ. Specifically, during laser surgery, the cornea of an eye is typically stabilized by a contact lens. This deforms the cornea. When the contact lens is removed after the surgery, the cornea recovers from the deformation. For the present invention, the angle Ψ is calculated, and corrected by the angle φ, so that surfaces altered during surgery (e.g. by LIOB) will become substantially parallel to incoming light in the eye, after the contact lens has been removed after surgery.

Claims (19)

1. A system for minimizing stray light caused by the creation of surfaces in intrastromal tissue of a cornea of an eye of a patient which comprises:

a contact lens having a contact surface having a radius of curvature “R c ” equal to approximately 10 mm, wherein the contact surface is engaged with the anterior surface of the eye, wherein the anterior surface of the eye has a radius of curvature “R” equal to approximately 7.8 mm and the contact lens is positioned thereon to introduce a predetermined deformation of the cornea;

a laser unit for directing a laser beam through the contact lens to alter corneal tissue over at least a portion of a cutting conical surface in the cornea, with the cutting conical surface having an increasing taper in a posterior direction along the visual axis of the eye, and wherein a reference point is selected on the anterior surface of the eye at a radial distance “s” from the visual axis, and wherein the cutting conical surface is inclined to compensate for the predetermined deformation with an induced deformation angle Ψ, with Ψ equal to arc sin s/R minus arc sin s/R c , and to compensate for refraction with an angle φ, with φ equal to arc sin s/ 20 ; and

a means for removing the contact lens from the eye for recovery of the eye from the deformation caused by the contact lens, with a consequent transition from the cutting conical surface to a refraction conical surface, where the induced deformation angle Ψ becomes effectively zero to minimize an introduction of stray light into the vision of the patient.

2. A system as recited in claim 1 wherein “s” is less than about two millimeters, wherein the angle Ψ is less than twenty five degrees, wherein the angle φ is less than five degrees, and wherein the laser unit generates a femtosecond laser beam.

3. A system as recited in claim 1 wherein an intersection between the cutting conical surface and the anterior surface of the eye is at a radial distance “s” from the visual axis.

4. A system as recited in claim 3 wherein a plurality of conical surfaces are involved, and each conical surface has a respective value for “s”.

5. A system as recited in claim 3 wherein “s” is less than about two millimeters.

6. A system as recited in claim 1 wherein the laser unit generates a femtosecond laser beam.

7. A system for minimizing stray light caused by the creation of surfaces in intrastromal tissue of a cornea of an eye of a patient which comprises:

a contact lens having a contact surface, wherein the contact surface is engaged with the anterior surface of the eye to introduce a predetermined deformation of the cornea;

a laser unit for directing a laser beam through the contact lens to alter corneal tissue over at least a portion of a cutting conical surface in the cornea, with the cutting conical surface having an increasing taper in a posterior direction along the visual axis of the eye, and wherein an intersection between the cutting conical surface and the anterior surface of the eye is at a radial distance “s” from the visual axis, and wherein the cutting conical surface is inclined to compensate for the predetermined deformation with an induced deformation angle Ψ and to compensate for refraction with an angle Φ; and

a means for removing the contact lens from the eye for recovery of the eye from the deformation caused by the contact lens, with a consequent transition from the cutting conical surface to a refraction conical surface, where the induced deformation angle Ψ becomes effectively zero to minimize an introduction of stray light into the vision of the patient.

8. A system as recited in claim 7 wherein the anterior surface of the eye has a radius of curvature “R” and the contact surface of the contact lens has a radius of curvature “R c ”, wherein R is equal to approximately 7.8 mm, and R c is equal to approximately 10 mm.

9. A system as recited in claim 8 wherein a reference point is selected on the anterior surface of the eye at the distance “s” from the visual axis, wherein the angle Ψ is equal to arc sin s/R minus arc sin s/R c , and wherein the refraction angle φ is equal to arc sin s/20.

10. A system as recited in claim 9 wherein “s” is less than about two millimeters, wherein the angle Ψ is less than twenty five degrees, wherein the angle φ is less than five degrees, and wherein the laser unit generates a femtosecond laser beam.

11. A system as recited in claim 7 wherein a plurality of conical surfaces are involved, and each conical surface has a respective value for “s”.

12. A system as recited in claim 7 wherein “s” is less than about two millimeters.

13. A system as recited in claim 7 wherein the laser unit generates a femtosecond laser beam.

Assignments (16)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 057821/0800) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: TECHNOLAS PERFECT VISION GMBH; BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 061884/0514 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 036400/0711) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 061775/0826 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0910 →
SECURITY AGREEMENT Recorded Aug 20, 2015
From: TECHNOLAS PERFECT VISION GMBH; DR. GERHARD MANN CHEM-PHARM. FABRIK GMBH
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 036400/0711 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2009
From: 20/10 PERFECT VISION AG
To: TECHNOLAS PERFECT VISION GMBH
Reel/Frame 023510/0024 →
CHANGE OF NAME Recorded Aug 6, 2009
From: 20/10 PERFECT VISION OPERATIONS GMBH
To: TECHNOLAS PERFECT VISION GMBH
Reel/Frame 023064/0750 →
CHANGE OF NAME Recorded Mar 4, 2009
From: 20/10 PERFECT VISION AG
To: 20/10 PERFECT VISION OPERATIONS GMBH
Reel/Frame 022345/0836 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2008
From: BILLE, JOSEF F.; LOESEL, FRIEDER
To: 20/10 PERFECT VISION AG
Reel/Frame 021350/0979 →